New Agreement Between Astra And Schering-plough

Report this content

NEW AGREEMENT BETWEEN ASTRA AND SCHERING-PLOUGH REGARDING RIGHTS TO IMDUR® IN THE U.S. For some time Schering-Plough has been marketing the drug isosorbide- 5-mononitrate, with the trademark Imdur, in the U.S. market under license from Astra. The product is used in the treatment of angina pectoris. This agreement was valid until 2004. A new agreement has now been reached which entails that Schering-Plough will receive an extension and broadening of the marketing rights to isosorbide-5-mononitrate in the U.S. Contact persons: Staffan Ternby, Vice President, PR & Information, Astra AB, +46 8 553 261 07 Mikael Widell, Press Officer, PR & Information, Astra AB, +46 8 553 264 28 Michael Olsson, Manager, Investor Relations, Astra AB, +46 8 553 259 52 Jörgen Winroth, Investor Relations U.S., Astra AB, +1 609 896 4148 ------------------------------------------------------------ Please visit http://www.bit.se for further information The following files are available for download: http://www.bit.se/bitonline/1998/12/08/19981208BIT00280/bit0001.doc http://www.bit.se/bitonline/1998/12/08/19981208BIT00280/bit0002.pdf

Documents & Links